| Literature DB >> 31711737 |
Abstract
Evidence is accumulating for seven and less fractions in localised prostate cancer, including one large randomised trial. However, there is much more evidence yet to come and changing practice in advance of this may be premature. We review the reasons to persist with moderate hypofractionation for prostate cancer radiotherapy, until the results of further phase III studies are known.Entities:
Keywords: Moderate hypofractionation; prostate cancer; radiotherapy
Year: 2019 PMID: 31711737 DOI: 10.1016/j.clon.2019.10.006
Source DB: PubMed Journal: Clin Oncol (R Coll Radiol) ISSN: 0936-6555 Impact factor: 4.126